Oncternal Therapeutics Inc (NAS:ONCT)
$ 8.179 -0.456 (-5.28%) Market Cap: 24.21 Mil Enterprise Value: -9.73 Mil PE Ratio: 0 PB Ratio: 0.80 GF Score: 50/100

Q3 2022 Oncternal Therapeutics Inc Earnings Call Transcript

Nov 03, 2022 / 09:00PM GMT
Release Date Price: $20 (-1.96%)
Operator

Ladies and gentlemen, Greetings, and welcome to the Oncternal Therapeutics, Inc. Q3 2022 Financial Results Call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Richard Vincent, Chief Financial Officer. Please go ahead, sir.

Richard G. Vincent
Oncternal Therapeutics, Inc. - CFO, Treasurer & Secretary

Thank you very much, Ryan. Good afternoon, everyone, and thank you for joining us today. Joining me on the call this afternoon are our President and CEO, Dr. James Breitmeyer; and our CMO, Dr. Salim Yazji. Today's call includes a business update and discussion for the third quarter ended September 30, 2022, which will be followed by Q&A. Today's press release and a replay of today's call will be available on the Investor Relations section of Oncternal's website for at least the next 30 days. Our 10-Q for the third quarter 2022 is also available today.

Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot